Category: 8. Health

  • Firth J, Gangwisch JE, Borisini A, Wootton RE, Mayer EA. Food and mood: how do diet and nutrition affect mental wellbeing? BMJ. 2020;369:m2382.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–312.

    Article 
    PubMed 

    Google Scholar 

  • Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet. 2021;397(10277):914–27.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Noorbala AA, Bagheri Yazdi SA, Yasamy MT, Mohammad K. Mental health survey of the adult population in Iran. Br J Psychiatry: J Mental Sci. 2004;184:70–3.

    Article 

    Google Scholar 

  • Liu RT, Walsh RFL, Sheehan AE. Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials. Neurosci Biobehav Rev. 2019;102:13–23.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhao M, Tuo H, Wang S, Zhao L. The Effects of Dietary Nutrition on Sleep and Sleep Disorders. Mediators Inflamm, 2020;3142874.

  • Sateia MJ. Update on sleep and psychiatric disorders. Chest. 2009;135(5):1370–9.

    Article 
    PubMed 

    Google Scholar 

  • Kirkbride JB, Anglin DM, Colman I, Dykxhoorn J, Jones PB, Patalay P, Pitman A, Soneson E, Steare T, Wright T, et al. The social determinants of mental health and disorder: evidence, prevention and recommendations. World Psychiatry. 2024;23(1):58–90.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Gammoh OS, Alqudah A, Abu Shaikh H, Al-Shudifat AE. Severe depressive symptoms in patients with hypertension: are antihypertensive medications implicated? Int J Psychiatry Med. 2024;59(1):6–19.

    Article 
    PubMed 

    Google Scholar 

  • Gammoh O, Al-Ameri M, Altaani G, Al-Smadi A, Al-Zegoul R, Massad T, Klaib AF, Alsous M, Binsaleh AY, Shilbayeh SAR. The Risk of Severe Fibromyalgia, Depression, Anxiety, and Insomnia Symptoms in Arab Women: An Implication of Self-Medication with Analgesics? A Cross-Sectional Study. Medicina (Kaunas) 2024;60(7).

  • Mancine RP, Gusfa DW, Moshrefi A, Kennedy SF. Prevalence of disordered eating in athletes categorized by emphasis on leanness and activity type – a systematic review. J Eat Disorders. 2020;8:47.

    Article 

    Google Scholar 

  • Burke LM, Collier GR, Hargreaves M. Glycemic index–a new tool in sport nutrition? Int J Sport Nutr. 1998;8(4):401–15.

    Article 
    PubMed 

    Google Scholar 

  • Murakami K, Miyake Y, Sasaki S, Tanaka K, Yokoyama T, Ohya Y, Fukushima W, Kiyohara C, Hirota Y. Dietary glycemic index and load and the risk of postpartum depression in japan: the Osaka maternal and child health study. J Affect Disord. 2008;110(1–2):174–9.

    Article 
    PubMed 

    Google Scholar 

  • Doherty R, Madigan S, Warrington G, Ellis J. Sleep and nutrition interactions: implications for athletes. Nutrients 2019;11(4).

  • Farrell K, Antoni MH. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril. 2010;94(5):1565–74.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Strydom H, Delport E, Muchiri J, White Z. The application of the food insulin index in the prevention and management of insulin resistance and diabetes: A scoping review. Nutrients 2024;16(5).

  • Elyasi L, Borazjani F, Ahmadi Angali K, Hosseini SA, Saki N. Dietary insulin index, dietary insulin load and dietary patterns and the risk of metabolic syndrome in Hoveyzeh cohort study. Sci Rep. 2024;14(1):1968.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31–55.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Darand M, Amirinejad A, Salehi-Abargouei A, Davies IG, Mirzaei M, Mazidi M, Khayyatzadeh SS. The association between dietary insulin index and load with mental health. BMC Psychol. 2022;10(1):218.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Anjom-Shoae J, Hassanzadeh Keshteli A, Afshar H, Esmaillzadeh A, Adibi P. Association between dietary insulin index and load and psychological disorders. Br J Nutr. 2020;123(2):161–71.

    Article 
    PubMed 

    Google Scholar 

  • Dehghan P, Nejati M, Vahid F, Almasi-Hashiani A, Saleh-Ghadimi S, Parsi R, Jafari-Vayghan H, Shivappa N, Hébert R. The association between dietary inflammatory index, dietary antioxidant index, and mental health in adolescent girls: an analytical study. BMC Public Health. 2022;22(1):1513.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zimorovat A, Moghtaderi F, Amiri M, Raeisi-Dehkordi H, Mohyadini M, Mohammadi M, Zarei S, Karimi-Nazari E, Mirzaei M, Nadjarzadeh A, et al. Validity and reproducibility of a semiquantitative Multiple-Choice food frequency questionnaire in Iranian adults. Food Nutr Bull. 2022;43(2):171–88.

    Article 
    PubMed 

    Google Scholar 

  • Perloff BP, Rizek RL, Haytowitz DB, Reid PR. Dietary intake methodology. II. USDA’s nutrient data base for nationwide dietary intake surveys. J Nutr. 1990;120(Suppl 11):1530–4.

    Article 
    PubMed 

    Google Scholar 

  • Holt SH, Miller JC, Petocz P. An insulin index of foods: the insulin demand generated by 1000-kJ portions of common foods. Am J Clin Nutr. 1997;66(5):1264–76.

    Article 
    PubMed 

    Google Scholar 

  • Amiri Khosroshahi R, Mirzababaei A, Setayesh L, Bagheri R, Heidari Seyedmahalleh M, Wong A, Suzuki K, Mirzaei K. Dietary insulin index (DII) and dietary insulin load (DIL) and Caveolin gene variant interaction on cardiometabolic risk factors among overweight and obese women: a cross-sectional study. Eur J Med Res. 2024;29(1):74.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zywiak WH, Stout RL, Trefry WB, Glasser I, Connors GJ, Maisto SA, Westerberg VS. Alcohol relapse repetition, gender, and predictive validity. J Subst Abuse Treat. 2006;30(4):349–53.

    Article 
    PubMed 

    Google Scholar 

  • Hamidi R, Fekrizadeh Z, Azadbakht M, Garmaroudi G, Taheri Tanjani P, Fathizadeh S, Ghisvandi E. Validity and reliability Beck depression Inventory-II among the Iranian elderly population. J Sabzevar Univ Med Sci. 2015;22(1):189–98.

    Google Scholar 

  • Vázquez Morejón AJ, Vázquez-Morejón Jiménez R, Zanin GB. Beck anxiety inventory: psychometric characteristics in a sample from the clinical Spanish population. Span J Psychol. 2014;17:E76.

    Article 
    PubMed 

    Google Scholar 

  • Khesht-Masjedi MF, Omar Z, Masoleh SK. Psychometrics properties of the Persian version of Beck anxiety inventory in North of Iranian adolescents. Int J Educ Psychol Res. 2015;1(2):145.

    Article 

    Google Scholar 

  • Zitser J, Allen IE, Falgàs N, Le MM, Neylan TC, Kramer JH, Walsh CM. Pittsburgh sleep quality index (PSQI) responses are modulated by total sleep time and wake after sleep onset in healthy older adults. PLoS ONE. 2022;17(6):e0270095.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mohammad Gholi Mezerji N, Naseri P, Omraninezhad Z, Shayan Z. The reliability and validity of the Persian version of Pittsburgh sleep quality index in Iranian people. Avicenna J Neuro Psycho Physiol. 2017;4(3):95–102.

    Article 

    Google Scholar 

  • Lange KW. Omega-3 fatty acids and mental health. Global Health J. 2020;4(1):18–30.

    Article 

    Google Scholar 

  • Kris-Etherton PM, Petersen KS, Hibbeln JR, Hurley D, Kolick V, Peoples S, Rodriguez N, Woodward-Lopez G. Nutrition and behavioral health disorders: depression and anxiety. Nutr Rev. 2021;79(3):247–60.

    Article 
    PubMed 

    Google Scholar 

  • Sarsangi P, Mohammadi M, Salehi-Abargouei A, Esmaillzadeh A, Mirzaei M. Dietary insulinemic potential, sleep quality and quantity in Iranian adults: Yazd health study and TAMYZ study. BMC Nutr. 2023;9(1):92.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cooper CB, Neufeld EV, Dolezal BA, Martin JL. Sleep deprivation and obesity in adults: a brief narrative review. BMJ Open Sport Exerc Med. 2018;4(1):e000392.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Watson AM. Sleep and athletic performance. Curr Sports Med Rep. 2017;16(6):413–8.

    Article 
    PubMed 

    Google Scholar 

  • Gill PA, Inniss S, Kumagai T, Rahman FZ, Smith AM. The role of diet and gut microbiota in regulating Gastrointestinal and inflammatory disease. Front Immunol. 2022;13:866059.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sánchez-Rosales AI, Guadarrama-López AL, Gaona-Valle LS, Martínez-Carrillo BE, Valdés-Ramos R. The Effect of Dietary Patterns on Inflammatory Biomarkers in Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2022;14(21).

  • Stanimirovic J, Radovanovic J, Banjac K, Obradovic M, Essack M, Zafirovic S, Gluvic Z, Gojobori T, Isenovic ER. Role of C-Reactive protein in diabetic inflammation. Mediators Inflamm. 2022;2022:3706508.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ma X, Nan F, Liang H, Shu P, Fan X, Song X, Hou Y, Zhang D. Excessive intake of sugar: an accomplice of inflammation. Front Immunol. 2022;13:988481.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rhie SJ, Jung EY, Shim I. The role of neuroinflammation on pathogenesis of affective disorders. J Exerc Rehabil. 2020;16(1):2–9.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Irwin MR. Sleep disruption induces activation of inflammation and heightens risk for infectious disease: role of impairments in thermoregulation and elevated ambient temperature. Temp (Austin). 2023;10(2):198–234.

    Google Scholar 

  • DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem. 2016;139(Suppl 2):136–53.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Tan S, Chen W, Kong G, Wei L, Xie Y. Peripheral inflammation and neurocognitive impairment: correlations, underlying mechanisms, and therapeutic implications. Front Aging Neurosci. 2023;15:1305790.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

Continue Reading

  • HIV treatment linked to risk of early knee osteoarthritis

    HIV treatment linked to risk of early knee osteoarthritis

    Acquired immune deficiency syndrome, or AIDS, caused by the human immunodeficiency virus (HIV), weakens the body’s immune system and can be life-threatening if left untreated. Although there is currently no cure for AIDS, the widespread use of antiretroviral therapies has successfully transformed what was once a fatal diagnosis into a manageable chronic condition. Given this increased life expectancy, the focus has now shifted to non-AIDS comorbidities such as cancer, diabetes, and even osteoarthritis (OA), since HIV-infected individuals are at a higher risk of developing these conditions than the general population. However, there has been controversy regarding the premature aging of knee joints and the prevalence of OA in HIV-infected individuals.

    Now, in a study published online on June 03, 2025, in the journal Bone Research, a team of researchers led by Dr. Zanjing Zhai at Shanghai Jiaotong University in Shanghai, China, has investigated the link between protease inhibitors (PIs), a class of drugs used to manage HIV, and the potential acceleration of OA development. In addition, they explored the underlying biological mechanisms that were responsible for this association.

    First, they studied a group of 151 HIV-infected individuals to observe if PIs (specifically, a combination of the drugs lopinavir and ritonavir) had any association with early development of OA in the knee. “Patients receiving PIs scored lower on the Knee Injury and Osteoarthritis Outcome Score questionnaire compared to those not receiving these medications, suggesting worse functional outcomes,” Dr. Zhai explains. Furthermore, X-ray imaging revealed a higher incidence of OA in the knees of patients treated with PIs.

    The researchers then evaluated the effect of various anti-HIV drugs on chondrocytes, the specialized cells comprising cartilage—a tissue in the knee joints that undergoes deterioration in patients with OA. Experiments on cultured chondrocytes as well as mice showed that among 25 anti-HIV drugs screened, lopinavir had the most detrimental effect on chondrocytes. Lopinavir treatment accelerated chondrocyte degradation and promoted senescence, a process in which cells permanently cease growth and division, thereby contributing to the OA development.

    How exactly do PIs accelerate OA development? To answer this, the researchers focused on the gene Zmpste24, which plays a role in arthritis and aging processes and has been previously reported to be inhibited by lopinavir. Interestingly, they found that lopinavir’s effects on chondrocytes were dependent on Zmpste24 expression. When the gene was ‘knocked out’ or not expressed, lopinavir no longer exacerbated chondrocyte degradation and senescence or worsened cartilage degeneration in mice.

    To understand the mechanism by which lopinavir-induced inhibition of Zmpste24 accelerates OA, they explored the underlying biological pathways and genes affected in this process. They found that Zmpste24 inhibition compromises nuclear membrane stability, which disrupts the interaction between Usp7 and Mdm2 proteins. This disruption activates the p53 signaling pathway, ultimately accelerating cartilage senescence. The study also revealed increasing the expression of Zmpste24 can have the opposite effect, i.e., it can reduce the OA severity in mice.

    How does this study impact the millions of people worldwide who are currently living with HIV? “This study provides new insights into PI-containing regimens and their relation to early OA development in people living with HIV and unveils a new mechanism underlying Zmpste24-related senescence,” explains Dr. Zhai. “Based on our findings, people living with HIV with elevated risk for knee OA should carefully consider their treatment options and choose other regimens when other effective alternatives are available.”

     

    Source:

    Shanghai Jiaotong University

    Journal reference:

    Kong, K., et al. (2025). AIDS patients suffer higher risk of advanced knee osteoarthritis progression due to lopinavir-induced Zmpste24 inhibition. Bone Research. doi.org/10.1038/s41413-025-00431-2.

    Continue Reading

  • The role of cd8+ t cells in tissue regeneration

    The role of cd8+ t cells in tissue regeneration

    In this interview, News Med talks to Prof. Uwe Ritter about the role of advanced imaging techniques in uncovering the role of CD8+ T cells in tissue regeneration.

    What are the main goals of your research into immune cell interactions and tissue regeneration?

    My work focuses on exploring immune cell interactions and tissue regeneration through cutting-edge imaging technologies, most notably the image processing and analysis pipelines of 3D skin models. These models are beneficial for characterizing regular T cells (Tregs) in wound healing.

    I am also using machine learning to analyze organoid cultures, particularly focused on investigating the impact of CD8+ T cells on tissue remodeling and the decryption of cell-cell interactions in situ.

    Mouse experiments involving the depletion of Tregs (pan depletion, subset-specific depletion, or induced depletion) have shown that Tregs are involved in immune regulation, metabolism, and tissue repair. These Tregs are characterized by the expression of amphiregulin and Foxp3.

    The repair function in murine systems is well established, but we would like to know whether or not there are equivalent tissue repair Tregs in humans.

    Michael Sforer’s group analyzed mouse and human tissues to investigate this equivalence. They analyzed blood, subcutaneous fat, and skin, performing single-cell attacks to look for any overlap in markers expressed by human or mouse Tregs to detect the phenotype of tissue repair Tregs in humans.

    This research revealed that it was possible to detect tissue Tregs in humans that express CCR8 and are positive for basic leucine zipper ATF-like transcription factor (BATF). These are comparable to tissue Tregs from the mouse immune system.

    Could you explain how imaging pipelines support the investigation of tissue regeneration processes?

    In the example I discussed, molecular analysis revealed that these tissue Tregs included Tfh, a molecular helper T cell differentiation program. This discovery offers a major advantage because we can generate Tfh-like tissue Tregs and naive T cells and look for functional analysis or tissue repair functions.

    The pipeline for this experiment involved isolating the tissue Tregs from PBMCs from blood and enriching them with CD25. We performed FACS sorting for the markers CD45 and CD45RA. We isolated antigen-naive Tregs and stimulated those naive Tregs with IL-2 to generate IL-2-derived Tregs. This allowed us to use Tfh-like Tregs similar to tissue Tregs, adding components such as IL-2, IL-12, IL-21, IL-23, and TGF-b.

    We added TransAct IL-2 to these T cells, allowing us to further activate and harvest the supernatant from these Tregs. This process gave us two supernatants from the IL-2 Tregs and putative repair Tregs from the tissue itself.

    What makes 3D skin models particularly useful for studying Tregs in wound healing? Could you expand on your work in this area?

    We contacted Florian Gruber in Vienna and Dirk Becker in Würzburg because this group had established a very useful 3D skin model involving growing human epidermal keratinocytes in plastic (PET) tubes.

    As the keratinocytes grow, they build up a strong epidermal compartment. A dermal punch can then be used to punch a hole into the epidermal compartment, and the keratinocytes start to close this area. This is essentially wound healing.

    We aimed to determine whether supernatants from Tfh-like Tregs or IL-2 Tregs better accelerate wound healing. Using a time kinetic approach, we cut the epidermal pieces in a cryostat.

    We aimed to measure the newly built stratum corneum in this structure. We needed to develop a software-based solution for dissecting structures from this epidermal compartment because we wanted to quantify the new stratum corneum in relation to the root healing effect of supernatant from the different Tregs I mentioned.

    The challenge was achieving the sophisticated color and structural separation to properly discern the epidermal tissue, the stratum granulosum, the stratum basale, and the polycarbonate matrix of the 3D skin model.

    The software detected the structures present in the epidermal compartment, reducing the impact of the background by subtracting the shades that do not correlate with the epidermal compartment. This is what allowed the stratum corneum to be detected.

    The software can be used to measure the number of keratinocytes in the epidermal compartment, and it is possible to use advanced color separation using special settings for tissue detection, polycarbonate detection, and more.

    The software’s capabilities were key to answering whether the supernatant could increase the wound healing in the system. The results showed that the IL-2 Treg supernatants did not have a significant impact on wound healing, but the Tfh-like cells supernatant saw the square micrometer of the stratum corneum become normalized.

    This technique can be reproduced via other methods such as trans-epithelial electrical resistance (TEER) measurements. Comparing these measurements showed similarity between the different approaches, confirming that the technique was working.

    We developed a detection algorithm that could dissect the pink shades of tissue. We also showed that tissue Tregs from humans are CCR8- and BAFT-positive and that these Tregs could accelerate wound healing in more complex wound-healing systems.

    Image Credit: Komsan Loonprom/Shutterstock.com

    How are you using machine learning with organoid cultures to study CD8+ T cells?

    CD8+ T cells are well known for their ability to kill virus-infected cells or tumor cells. CD8+ T cells in the dysfunctional state (called exhaustion) are positive for PD1, TIGIT, and other markers.

    Immunity is not black and white, however. In systems like liver hepatocellular carcinoma or NASH, it has been shown that CD8+ T cells that are PD1+ and TIGIT+ are reactive. They are not exhausted and can promote fibrosis or tumor progression.

    We want to know whether these CD8+ T cells are involved in tissue reconstruction. When CD8+ T cells kill infected cells, we see tissue destruction that requires remodeling. Therefore, we can ask whether CD8+ T cells can also induce tissue regeneration.

    To investigate this, we isolated those T cells and stimulated those CD8+ T cells using CD3 and CD28 beads. We took the resulting supernatant and performed an easy scratch assay. Activated naive T cells are not useful in wound healing, but we did observe that activated PD1+, TIGIT+, and activated central memory T cells can induce wound healing.

    We also wanted to know whether CD8+ cells can promote organoids’ reorganization. To investigate this, we isolated CD8+ T cells using the TexMACS medium, activated those T cells (because only activated CD8+ T cells can induce wound healing), and added them to organoids.

    Organoids are simple tissue-engineered cell-based in vitro models that recapitulate many aspects of the complex structures and functions of corresponding in vivo tissues. Organoids are tissue-derived and we can derive them from adult stem cells.

    Cancer stem cells are induced through pretense stem cells, so this is not a problem. We can generate organoids in a Matrigel dome, so we opted to use this approach.

    For example, we wanted to know what happens when the organoids come into close contact with lymphocytes. This had not been done before our study because measuring and dissecting organoids from lymphoids is very difficult.

    With this in mind, our goal was to develop a machine learning pipeline suitable for detecting organ structures within the complex co-culture and high-throughput conditions. This had to include the characterization of organ formation, including numbers, size, and shape.

    We began by deriving organoids from the bile duct and combining them with CD8+ T cells. Then, we started working in collaboration with TissueGnostics to develop an organoid detection app.

    A number of problems had to be addressed at the beginning of this process. For example, we saw contour mimicry whereby cells look like organoids but are not organoids. We also saw contour fusion, with a fusion of two organoids that are difficult to dissect, and contour disruption, which makes it difficult for the algorithm to detect the organoid structure.

    The software takes the organoid image, converts it to grayscale, and performs a background correction. The software then allows one to see the membrane of the organoids, distinguishing between the membrane and the organoids and the background of the lymphocytes and other structures. Corrections can be applied as required to better split the background from the organoids and implement a layer specification of the organoids.

    It is also possible to adjust size and compactness when you are not confident or happy with the results.

    We used the classifier machine learning system to improve this new system. For example, it is possible to train the algorithm by manually marking the tissue and marking the organoid boundary.

    This type of manual delineation is time-consuming, but it was a useful quality control measure. We used a linear regression model to compare organoid size using both manual detection and software detection, confirming that the app is very precise and that it can be used to perform studies.

    Results showed an increase in CD8+ cells from different donors. We measured the total area and sum of the organoids, showing an increase in organoid development in the presence of CD8+ T cells.

    Our findings also indicate that the cytotoxic effector program of CD8+ cells is closely linked to a regeneration program, both of which are evoked upon a teaser stimulation. CD8+ T cells can kill other cells, but they also induce a tissue regeneration program.

    What are your visions for decoding cell-cell interactions in situ using advanced imaging technologies?

    I think we will be able to effectively decode cell-cell interactions in a few years. Cell communication between immunological cells such as T cells or dendritic cells is often based on autocrine signaling or juxtaposition processes. These processes influence tissue homeostasis and immune response to tumors and pathogens.

    There are signaling molecules involved, for example, cytokines, metabolites, receptor proteins that bind specific surface molecules, signaling pairs, cell junctions, and secondary messengers. In terms of understanding this communication, we know the alphabet, but we do not currently understand the sentences.

    Many people are already working with single-cell RNA-seqs and single-cell FACS analysis, allowing them to describe the transcriptome and phenotype of each single cell. However, we still do not know which cell has been in contact with other cells or which cell is responsible for activating other cells. These questions cannot be answered via single-cell analysis.

    We can generate single-cell raw data at the transcriptome, proteome, or metabolome level, but this is the limit at the moment.

    We can perform very simple in vitro experiments. For example, we can evaluate OT-1 T cells specific for ovalbumin by adding ovalbumin to an in vitro culture with dendritic cells and measuring the immune response of the dendritic and T cells.

    We can also use laser scanning microscopy to measure the membrane overlaps of cells (immunological synapse) to characterize the phenotype of cells that interact with dendritic cells. This approach is very precise, but it only describes the phenotypes.

    We can also do this in situ, measuring cell boundaries via the StrataQuest software. This allows us to calculate the potential contact area of cells, analyzing the cells that are in direct contact with the analyzed cell to characterize its neighbors. However, this method does not show whether cells are in communication.

    We have performed experiments. We took APCs, defined endogen, a T cell receptor, and added ovalbumin. We then measured single-cell and double-cell effects with RNAseq and dcRNAseq. After sorting the droplets, we analyzed the phenotype modification or the transcriptome of those cells interacting in terms of their phenotype modification or non-phenotype modification.

    How does your work in this area correlate with the PIC-seq methods developed by Ido Amit’s lab?

    It is closely aligned. In 2020, an excellent publication by Ido Amit described a similar approach to ours. They did exactly the same. They kept it simple, used APCs, defined a TCR receptor, isolated the T cells and dendritic cells, and then conjugated doublets. They then performed single-cell analysis and physically interacting cells (PIC) analysis.

    This allowed them to develop a PIC-seq algorithm that enabled the dissection of dendritic cells and T cells. This PIC-seq approach allowed the team to analyze the core signature of the attached dendritic cells or T cells.

    This is very important because this approach removes the need to isolate and dissect doublets, allowing us to begin to characterize the crosstalk of physically interacting cells.

    However, it is important to note that this approach is only possible when the two cell subsets are transcriptionally distant. When they are transcriptionally related, this technique is not functional.

    I became fascinated with this technique and wrote an opinion article about it that was published this year. I explained that it is possible to analyze single cells, analyze PICs, sequence single cells on the PICs, and run the PIC-seq. This is based on the pre-processing, integration, deconvolution, and differentiation of the data.

    My idea was that it is also possible to define the gene expression profiles of PICs grouped by the contributing T cell or myeloid identity. For example, it would be possible to characterize migratory DCs based on their genes, plasmacytoid DCs, DC-1, DC-2, or monocytes. A similar definition is possible with T cells, for example, characterizing a naive T cell, CD4+ Treg, CD8+ CTL, or an activated T cell.

    When we know the profile of physically interacting cells based on experimental data with ovalbumin or other antigens, we can determine the gene profiles of migratory antigen-presenting TCs and know exactly what they are producing.

    This allows us to create a panel, choosing antibodies with fluorescence, for example, and performing multiplex staining.

    This requires a microscope capable of imaging multiple channels. The key advantage of this approach is that we can detect the cells that are genuinely interacting based on the presence of specific markers.

    What types of research do you see potentially evolving from these approaches?

    This approach is potentially valuable for mouse systems where, for example, we can infect mice with pathogens, and because we know we have a resistant phenotype and a chronic phenotype, we can detect the gene modules that correlate to adaptive immunity by T cells or dendritic cells that correlate to immune pathology.

    There are differences between viruses, protozoans, and bacteria, but this approach could lead to the creation of a multicenter-based contextual and PIC atlas, featuring relevant gene modules and a pathogen-specific background.

    For example, during the immune response of the PICs, we may see shared expressions of genes also induced by protozoans or bacteria. The software could be used to detect genes that are exclusively induced by virus infection. We could isolate these genes using future software packages, demonstrate these findings, and relate these back to the in situ situation, clearly showing or describing the cells in communication in a pathogen-specific manner.

    These findings could also eliminate the need to work with dendritic and T-cells. We may see this concept expand into other systems, such as tumor immunology. It may become possible to characterize gene models associated with tumor-killing based on the interaction between cells and the expression of genes that are specifically induced during tumor-killing processes.

    This type of computational analysis will allow us to pinpoint biomarkers, for example, that are associated with tumor immune cell interaction. The advantages of these systems are clear: they allow us to deepen our understanding of tumor immune communications, identify tumor gene modules, and characterize tumor escape mechanisms.

    I also think this will improve the interpretation of tumor-effector cell interactions in situ, which will be crucial for evaluating tumor progression and treatment activities.

    About Prof. Uwe Ritter

    Prof. Uwe Ritter is a principal investigator in the Department of Immunology, Leibniz institute for Immunotherapy. His research is focused on studying the immune system’s response to various antigens in the skin-associated lymphatic tissue (SALT). He and his team aim to manipulate critical immune checkpoints in myeloid cells to potentially reprogram dysfunctional immune reactions. Their work integrates cutting-edge technologies – notably in-situ contextual tissue cytometry and high-resolution imaging – to gain deeper insights into tissue structure and function.

    About TissueGnostics

    TissueGnostics (TG) is an Austrian company focusing on integrated solutions for high content and/or high throughput scanning and analysis of biomedical, veterinary, natural sciences, and technical microscopy samples.

    TG has been founded by scientists from the Vienna University Hospital (AKH) in 2003. It is now a globally active company with subsidiaries in the EU, the USA, and China, and customers in 30 countries.

    TissueGnostics portfolio

    TG scanning systems are currently based on versatile automated microscopy systems with or without image analysis capabilities. We strive to provide cutting-edge technology solutions, such as multispectral imaging and context-based image analysis as well as established features like Z-Stacking and Extended Focus. This is combined with a strong emphasis on automation, ease of use of all solutions, and the production of publication-ready data.

    The TG systems offer integrated workflows, i.e. scan and analysis, for digital slides or images of tissue sections, Tissue Microarrays (TMA), cell culture monolayers, smears, and other samples on slides and oversized slides, in Microtiter plates, Petri dishes and specialized sample containers. TG also provides dedicated workflows for FISH, CISH, and other dot structures.

    TG analysis software apart from being integrated into full systems is fully standalone capable and supports a wide variety of scanner image formats as well as digital images taken with any microscope.

    TG cooperations

    TG continuously cooperates with research groups and other companies in the industry to provide novel tools and applications to its customers.


    Continue Reading

  • Uterine cancer deaths expected to rise sharply in the United States by 2050

    Uterine cancer deaths expected to rise sharply in the United States by 2050

    Bottom Line: Uterine cancer incidence and mortality rates are projected to increase significantly over the next three decades in the United States, with incidence-based mortality expected to be nearly three times higher in Black women compared with white women by 2050.

    Journal in Which the Study was Published: Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR)

    Author: Jason D. Wright, MD, chief of the Division of Gynecologic Oncology at Columbia University

    Background: While incidence and mortality rates for most cancer types have been on the decline in the United States, cases of uterine cancer increased an average of 0.7% each year between 2013 and 2022 and age-adjusted death rates increased 1.6% annually between 2014 and 2023, according to the Surveillance, Epidemiology, and End Results (SEER) Program at the National Cancer Institute (NCI). Black women are disproportionally affected with a death rate from uterine cancer that is about twice as high compared with women of other races or ethnicities. 

    Overall, uterine cancer is one of the few cancers where both incidence and mortality have been increasing, and prior studies have consistently shown significant racial disparities among Black and white women. Understanding future trends will help inform the development of robust strategies to reduce the burden and improve outcomes.” 


    Jason D. Wright, MD, lead author of the study

    How the Study was Conducted: As part of the NCI’s Cancer Intervention and Surveillance Modeling Network (CISNET), Wright and his colleagues built the Columbia University Uterine Cancer Model (UTMO). This natural history model of uterine cancer simulates the trajectories for incidence and mortality based on characteristics from a sample population, taking into account factors such as age (between 18 and 84), race (Black and white), birth cohort (grouped in 10-year intervals starting in 1910-1920), stage (as determined by the American Joint Committee on Cancer), and histologic subtype (the more common endometrioid uterine cancer vs. non-endometrioid cancers, which tend to have a worse prognosis). Survival estimates are based on current available treatments with the model unable to account for potential advances in therapeutics. 

    To validate the model, Wright and his team used UTMO to predict the median age of diagnosis, survival rate, and distribution of diagnosis by stage for uterine cancer in 2018, and found those projections were comparable to the actual SEER data from that year. 

    Following this validation, they estimated the future rates of uterine cancer based on publicly available sources through 2018.

    Results: Incidence was projected to increase from 57.7 cases per 100,000 in 2018 to 74.2 cases per 100,000 in 2050 for white women and from 56.8 cases per 100,000 to 86.9 cases per 100,000 for Black women. Incidence-based mortality was projected to increase from 6.1 per 100,000 to 11.2 per 100,000 among white women and from 14.1 per 100,000 to 27.9 per 100,000 among Black women. 

    Further, while the incidence of endometrioid tumors is projected to increase considerably in both Black (34.2 per 100,000 to 50.5 per 100,000) and white (49.2 per 100,000 to 63.4 per 100,000) women, the increased incidence of non-endometrioid tumors was more significant in Black (from 22.5 per 100,000 to 36.3 per 100,000) than white (from 8.5 per 100,000 to 10.8 per 100,000) women. 

    The model also showed that should hysterectomy rates continue to decrease and obesity rates continue to increase, the incidence and mortality rates for uterine cancer would increase more drastically for both white and Black women. Obesity is a known risk factor for uterine cancer, and while an increase in the use of obesity treatments like GLP-1s could instead cause obesity rates to decline, Wright explained it is hard to predict if that will be the case. Hysterectomy is known to reduce the risk of uterine cancer, but due to the availability of nonsurgical treatments for gynecologic disease, hysterectomy rates are projected to decline 25.7% from 2020 to 2035. 

    Author’s comments: “There are likely a number of factors that are associated with the increased burden of uterine cancer in Black women,” Wright said. “They more commonly have aggressive types of uterine cancer, face delayed diagnosis resulting in later-stage disease at diagnosis, and there are often delays in their treatment.”

    Wright and his colleagues also performed a stress test of the model by incorporating hypothetical screening and intervention methods that could detect uterine cancer and precancerous changes prior to clinical diagnosis. The screening and intervention methods were most effective when introduced at age 55 with declines in cancer incidence that lasted up to 15 years in white women and up to 16 years in Black women. 

    “The stress testing suggests that if there was an effective screening test, we may be able to substantially reduce the burden of disease,” Wright said. “While there is presently no screening or prevention that is routinely used for uterine cancer, we are currently examining the potential impact of integrating screening for this cancer into practice.” 

    Study limitations: Limitations of the study include the fact that the model is based only on population-level estimates, and some of the risk factors, though representing the highest quality of data available, could be outdated. Additionally, not all potential risk factors for uterine cancer were incorporated into the model, but Wright said they are working to develop more precise estimates of other risk factors. Other limitations include the smaller number of annual cases of non-endometrioid tumors, lack of data on uterine sarcomas, and inclusion of data on only Black and white women. 

    Funding & disclosures: The study was supported by funds from the NCI. Wright has received royalties from UpToDate, honoraria from the American College of Obstetricians and Gynecologists, and research support from Merck. 

    Source:

    American Association for Cancer Research

    Journal reference:

    Wright, J. D., et al. (2025) Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States. Cancer Epidemiology Biomarkers & Prevention. doi.org/10.1158/1055-9965.EPI-24-1422.

    Continue Reading

  • Q2 2025 Recap: Ophthalmology News and Updates

    Q2 2025 Recap: Ophthalmology News and Updates

    Ophthalmology has been on a tremendous rise in recent years, with developments on almost every front and new treatments for a slew of diseases. Upcoming therapies and groundbreaking technology have paved the way for attempts to lighten the treatment burden on patients by extending dosing intervals; a number of medications have exhibited efficacy outside of their expected field in ophthalmology; and trial successes have come hard and fast.

    Q2 2025 followed many of these patterns, with the US Food and Drug Administration (FDA) handing out approvals to several critically important medications and companies worldwide announcing successful advancements on first-of-their-kind drugs. Niches were filled, treatment burdens were lessened, and alternative therapies were discovered. To mark the end of Q2 2025, HCPLive Ophthalmology created a recap of the biggest news from April to June 2025.

    This recap collects 5 regulatory updates from the FDA, our 5 biggest trial announcement articles, and 3 critical insights from top experts featured prominently within our coverage.

    Q2 2025 Regulatory Updates in Ophthalmology

    FDA Issues Complete Response Letter to Aflibercept 8 mg for Extended Dosing

    Announced on April 18, this CRL was specifically for parent company Regeneron’s proposed dosage extension up to 24-weeks. No safety or efficacy issues of aflibercept 8 mg in any of its approved dosing regimens or indications were found; the FDA disagreed instead with an attempt to extend dosing intervals longer than the current maximum of 16 weeks according to the label.

    FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation

    On June 12, 2025, the FDA approved the sterile, topical anti-inflammatory agent for the treatment of steroid-responsive ocular inflammation. The medication is a self-administered eye drop intended for use 2-4 times daily. In addition to this approval, parent company Amneal Pharmaceuticals announced a planned launch for the third quarter of 2025.

    FDA Approves Acoltremon Ophthalmic Solution (TRYPTYR) for Dry Eye Disease

    On May 28, 2025, the FDA approved acoltremon, a first-in-class transient receptor potential melastatin 8 channel receptor agonist which stimulates corneal sensory nerves, to treat dry eye disease. Both pivotal phase 3 trials, COMET-2 and COMET-3, displayed rapid onset and sustained tear production, as well as a substantial percentage of patients with a ≥10mm increase in unanesthetized Schirmer’s score across both trials compared to vehicle.

    FDA Approves Susvimo for Treatment of Diabetic Retinopathy

    Announced on May 22, 2025, this approval marked the third approved indication for Susvimo, along with diabetic macular edema. The medication was made available to US retina specialists from the day that parent company Genentech announced the FDA approval. Susvimo is now the first and only FDA-approved continuous delivery treatment able to maintain vision in people with diabetic retinopathy with only 1 refill every 9 months.

    FDA Grants IND Clearance to Immunoglobulin Eye Drops for Dry Eye Disease

    On May 21, 2025, the FDA granted Investigational New Drug clearance to Selagine, Inc.’s immunoglobulin drops, an anti-inflammatory and immunomodulatory biologic drug for the treatment of dry eye disease. Selagine and partner Grifols, one of the leading producers of plasma-derived medicines, expect that the IG drops will reach retail pharmacies in early 2029.

    Q2 2025 Trial Announcements in Ophthalmology

    VVN461 Trial Topline Results Announced for Non-Infectious Anterior Uveitis

    Announced April 24, 2025, VivaVision announced that both VVN461-1.0% and VVN461-0.5% showed non-inferior efficacy against a prednisolone acetate comparator cohort in treating NIAU. Although VivaVision is based in China, the company has announced its intention to request a type C meeting with the FDA regarding phase 3 trials and an eventual BLA.

    Pegcetacoplan Reduces Rate of Geographic Atrophy Growth, 1-Year Trial Data Shows

    On April 23, 2025, 12-month results from the ongoing GALE open-label extension study indicated pegcetacoplan’s ability to reduce the mean rate of geographic atrophy growth. Initiated in response to positive results from the 2-year OAKS and DERBY trials of pegcetacoplan in patients with GA secondary to AMD, GALE is expected to significantly advance the evidence for the medication’s long-term safety and efficacy by its culmination.

    Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial

    Announced by Cognition Therapeutics on May 8, 2025, the phase 2 MAGNIFY trial resulted in oral zervimesine reducing lesion growth in patients with geographic atrophy secondary to age-related macular degeneration. Simultaneously being developed for Alzheimer’s and dementia with Lewy bodies, the once-daily oral pill may overcome the limitations of current treatment options, which require regular intravitreal injections.

    Veligrotug Shows Durability for Thyroid Eye Disease in Phase 3 Trial Results

    Long-term data announced on May 20, 2025, by Viridian Therapeutics, Inc. indicated the positive long-term durability of veligrotug in treating thyroid eye disease. Veligrotug, already granted the Breakthrough Therapy designation by the FDA prior, is also on track with its BLA planned for the second half of 2025.

    Opthea Announces Termination of ShORe and COAST Trials of Sozinibercept

    On April 2, 2025, Opthea announced the termination of their ShORe and COAST trials after sozinibercept failed to achieve vision improvement benchmarks in treating wet AMD. COAST failed on March 24, which led Opthea to accelerate topline data of the ShORe trial. However, when this trial also missed its benchmarks, Opthea shuttered the trials.

    Q2 Expert Perspectives in Ophthalmology

    Phase 2 LUNA Trial Results for Ixo-vec to Treat Neovascular AMD with Dante Pieramici, MD

    Dante Pieramici, MD, assistant clinical professor of ophthalmology at the Doheny Eye Center in Southern California, discusses the results of the phase 2 LUNA trial of ixoberogene Soroparvovec intravitreal gene therapy for the treatment of neovascular age-related macular degeneration.

    Changing Dosage Regimens in Patients with Diabetic Macular Edema, with Mark Barakat, MD

    Mark Barakat, MD, founder and director of research at the Retina Macula Institute of Arizona, discusses his post-hoc analysis examining the shortening or extending of aflibercept 8 mg dosage for patients with DME through week 96 of the PHOTON trial.

    Switching to Aflibercept 8 mg in Treatment-Experienced Patients with Ted Leng, MD

    Theodore Leng, MD, Director of Clinical and Translational Research and Director of Ophthalmic Diagnostics at the Stanford University School of Medicine, discusses the process of switching to aflibercept 8mg from other anti-VEGF agents in patients with neovascular age-related macular degeneration.

    Continue Reading

  • Oral drug MA-5 can improve heart and muscle problems in Barth syndrome

    Oral drug MA-5 can improve heart and muscle problems in Barth syndrome

    Researchers at Tohoku University have discovered that an oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare genetic disorder affecting 1 in 300,000 births worldwide with no current cure.

    Barth syndrome is caused by mutations in the TAZ gene that leave patients—mostly young boys—with weakened hearts, muscle fatigue, and increased rates of infection. Many require heart transplants, and current treatments only manage symptoms without addressing the underlying cause.

    The research team, led by Professors Takaaki Abe, and Takafumi Toyohara, and first author Yoshiyasu Tongu, tested MA-5 on cells from four Barth syndrome patients and in fruit fly (Drosophila) models of the disease. Published in The FASEB Journal on June 21, 2025, their findings reveal that MA-5 boosted cellular energy (ATP) production by up to 50% and protected cells from oxidative stress-induced death.

    What excites us most is that MA-5 works by targeting the fundamental problem in Barth syndrome—defective energy production in mitochondria. Unlike current treatments that only manage symptoms, MA-5 actually improves the root cause of how cells generate energy.”


    Professor Takaaki Abe

    MA-5 was chosen as a treatment because it enhances interactions between two crucial mitochondrial proteins—mitofilin and ATP synthase—leading to more efficient energy production. As such, this mechanism directly addresses the cause of cellular dysfunction in Barth syndrome.

    In human muscle cells derived from Barth syndrome iPS cell models, MA-5 corrected abnormal mitochondrial structures and reduced cellular stress markers. When tested in Drosophila with Barth syndrome, the drug dramatically improved their climbing ability (capacity for physical exertion) and normalized their elevated heart rates—two key symptoms that mirror how the disease affects humans. Furthermore, MA-5 restored normal mitochondrial structure in the Drosophila muscle tissue.

    These promising results suggest that MA-5 addresses the largest challenges faced by patients with Barth syndrome, which would significantly improve their quality of life. Phase I clinical trials in Japan have been completed successfully, and the research team is preparing to start Phase II trials soon.

    “We’ve validated MA-5 using patient cells, iPS cell models and a Drosophila model of Barth syndrome,” remarks Abe. “The evidence from all of these studies supports its potential effectiveness in patients with Barth syndrome, which we hope to examine more in the next clinical trial.”

    Considering the limited options for treatment currently available, this research provides hope for a better future for patients and their families. Critically, MA-5 can be taken orally, which makes administration significantly easier for pediatric patients. It is the first oral medication for Barth syndrome to progress to the clinical trial stage.

    The team’s findings suggest that MA-5 could become the first disease-modifying treatment for Barth syndrome, offering new therapeutic options beyond current symptomatic management.

    The research was supported by grants from JSPS KAKENHI, AMED, and other Japanese research foundations.

    Continue Reading

  • Association Between a Diabetes Risk Reduction Diet and Mortality From Chronic Liver Disease

    Association Between a Diabetes Risk Reduction Diet and Mortality From Chronic Liver Disease


    Continue Reading

  • Air Pollution Exposure May Cause Heart Damage

    Air Pollution Exposure May Cause Heart Damage


    Register for free to listen to this article

    Thank you. Listen to this article using the player above.


    Want to listen to this article for FREE?


    Complete the form below to unlock access to ALL audio articles.

    Long-term exposure to fine particulate air pollution may contribute to subtle heart tissue changes associated with the early signs of heart damage, according to research published in Radiology.

    The study, which used cardiac MRI, found a connection between higher exposure to particulate matter and diffuse myocardial fibrosis – microscopic scarring in the heart muscle.

    Although the relationship between air pollution and cardiovascular disease is well established, the specific tissue-level changes driving this risk remain unclear. This investigation aimed to clarify that link using imaging-based assessments of myocardial health.

    MRI reveals early signs of fibrosis

    The study examined 694 individuals in total, including 201 healthy participants and 493 people with dilated cardiomyopathy. Researchers measured each participant’s myocardial extracellular volume, a marker of fibrosis, using cardiac MRI. These values were then compared with estimates of long-term exposure to fine particulate matter, also known as PM2.5.

    PM2.5 refers to airborne particles with a diameter of 2.5 micrometers or smaller. These particles are small enough to be inhaled deeply into the lungs and pass into the bloodstream. Common sources include traffic emissions, industrial activity and wildfires.

    “We know that if you’re exposed to air pollution, you’re at higher risk of cardiac disease, including higher risk of having a heart attack,” said the study’s senior author Kate Hanneman, MD, MPH, from the Department of Medical Imaging at the Temerty Faculty of Medicine, University of Toronto and University Health Network in Toronto. “We wanted to understand what drives this increased risk at the tissue level.” 

    Participants with higher long-term exposure to PM2.5 exhibited greater levels of myocardial fibrosis. This association held true for both healthy individuals and those with existing heart disease. The most pronounced effects were observed in women, people who smoke and individuals with hypertension.

    Reinforcing pollution as a risk factor

    The findings contribute to a growing body of evidence suggesting that air pollution is an independent cardiovascular risk factor. This risk persists even when other major contributors, such as smoking and high blood pressure, are accounted for. The study also showed that health impacts may occur even when pollution levels fall below current global guidelines.

    “Even modest increases in air pollution levels appear to have measurable effects on the heart,” Hanneman said. “Our study suggests that air quality may play a significant role in changes to heart structure, potentially setting the stage for future cardiovascular disease.”

    “Public health measures are needed to further reduce long-term air pollution exposure,” continued Hanneman. “There have been improvements in air quality over the past decade, both in Canada and the United States, but we still have a long way to go.”  

    This research may support efforts to improve cardiovascular risk prediction. For example, air pollution exposure history could help clinicians refine risk assessments for patients in high-exposure settings, including outdoor workers or those living in highly polluted regions.

    The results also underscore the role of radiologists and medical imaging in environmental health research. 

    “Medical imaging can be used as a tool to understand environmental effects on a patient’s health,” Hanneman said. “As radiologists, we have a tremendous opportunity to use imaging to identify and quantify some of the health effects of environmental exposures in various organ systems.” 

    Reference: Du Plessis J, DesRoche C, Delaney S, et al. Association between long-term exposure to ambient air pollution and myocardial fibrosis assessed with cardiac MRI. Radiology. 2025. doi: 10.1148/radiol.250331

    This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

    This content includes text that has been generated with the assistance of AI. Technology Networks’ AI policy can be found here.

    Continue Reading

  • Is cheese secretly fueling your nightmares? Science weighs in

    Is cheese secretly fueling your nightmares? Science weighs in

    Scientists have found that eating too much dairy could ruin your sleep. Researchers questioned more than 1,000 students about the quality of their sleep, their eating habits, and any perceived link between the two, and found a strong association between nightmares and lactose intolerance — potentially because gas or stomach pain during the night affects people’s dreams.

    “Nightmare severity is robustly associated with lactose intolerance and other food allergies,” said Dr Tore Nielsen of Université de Montréal, lead author of the article in Frontiers in Psychology. “These new findings imply that changing eating habits for people with some food sensitivities could alleviate nightmares. They could also explain why people so often blame dairy for bad dreams!”

    Sweet dreams?

    Although folk beliefs have long held that what you eat affects how you sleep, there’s very little evidence to prove or disprove them. To investigate, researchers surveyed 1,082 students at MacEwan University. They asked about sleep time and quality, dreams and nightmares, and any perceived association between different kinds of dreams and different foods. They also asked about participants’ mental and physical health and their relationship with food.

    About a third of respondents reported regular nightmares. Women were more likely to remember their dreams and to report poor sleep and nightmares, and nearly twice as likely as men to report a food intolerance or allergy. About 40% of participants said that they thought eating late at night or specific foods affected their sleep; roughly 25% thought particular foods could make their sleep worse. People who ate less healthily were more likely to have negative dreams and less likely to remember dreams.

    “We are routinely asked whether food affects dreaming — especially by journalists on food-centric holidays,” said Nielsen. “Now we have some answers.”

    Cheesy culprits

    Most participants who blamed their bad sleep on food thought sweets, spicy foods, or dairy were responsible. Only a comparatively small proportion — 5.5% of respondents — felt that what they ate affected the tone of their dreams, but many of these people said they thought sweets or dairy made their dreams more disturbing or bizarre.

    When the authors compared reports of food intolerances to reports of bad dreams and poor sleep, they found that lactose intolerance was associated with gastrointestinal symptoms, nightmares, and low sleep quality. It’s possible that eating dairy activates gastrointestinal disturbance, and the resulting discomfort affects people’s dreams and the quality of their rest.

    “Nightmares are worse for lactose intolerant people who suffer severe gastrointestinal symptoms and whose sleep is disrupted,” said Nielsen. “This makes sense, because we know that other bodily sensations can affect dreaming. Nightmares can be very disruptive, especially if they occur often, because they tend to awaken people from sleep in a dysphoric state. They might also produce sleep avoidance behaviors. Both symptoms can rob you of restful sleep.”

    Eat well to sleep well?

    This could also explain why fewer participants reported a link between their food and their dreams than in a previous study by Nielsen and his colleague Dr Russell Powell of MacEwan University, conducted eleven years earlier on a similar population. Improved awareness of food intolerances could mean that the students in the present study ate fewer foods likely to activate their intolerances and affect their sleep. If this is the case, then simple dietary interventions could potentially help people improve their sleep and overall health.

    However, besides the robust link between lactose intolerance and nightmares, it’s not clear how the relationship between sleep and diet works. It’s possible that people sleep less well because they eat less well, but it’s also possible that people don’t eat well because they don’t sleep well, or that another factor influences both sleep and diet. Further research will be needed to confirm these links and identify the underlying mechanisms.

    “We need to study more people of different ages, from different walks of life, and with different dietary habits to determine if our results are truly generalizable to the larger population,” said Nielsen. “Experimental studies are also needed to determine if people can truly detect the effects of specific foods on dreams. We would like to run a study in which we ask people to ingest cheese products versus some control food before sleep to see if this alters their sleep or dreams.”

    Continue Reading

  • Cambodia, South Korea record new avian flu cases in poultry

    Since mid-June, Cambodia’s veterinary authority has confirmed six further highly pathogenic avian influenza (HPAI) outbreaks in poultry flocks.

    Based on official notifications to the World Organisation for Animal Health (WOAH), these bring the nation’s total outbreaks over the past 12 months to 16. Directly impacted have been close to 8,000 domestic birds.

    In the recent outbreaks, village flocks affected ranged in size from 25 to more than 650 birds. Two were in Pursat — the first infections in this western province. There were also two outbreaks in each of Takeo and Siem Reap, which are located in the far south and northwest of the country, respectively.

    Detection of the H5N1 serotype of the HPAI virus at one of the Takeo province outbreaks was confirmed after an infection was suspected in a resident of the village. Sick or dead poultry at the other locations raised suspicions of HPAI in the other village flocks. 

    2 more outbreaks in South Korean poultry

    Over the past two weeks, HPAI outbreaks linked to the same virus variant have been confirmed in two poultry flocks. The first ended a near two-month hiatus in South Korea.

    Testing positive for the virus in mid-June was a flock of around 28,000 birds at a farm in the central province of North Chungcheong, according to the latest WOAH notification. 

    According to the agriculture ministry, the infection was revealed in ducks as a result of routine pre-shipment testing.

    Just last week, a flock of around 1,000 native chickens tested positive for the same virus at a premises in the southeastern province of South Gyeongsang.

    The ministry reports that the farm was not authorized to keep livestock, and numerous biosecurity-related deficiencies emerged during the follow-up inspection there.

    Following this latest development, the authorities have increased surveillance of native chicken flocks, as well as dealers and traditional markets that handle these birds. Furthermore, for a period of 14 days, the proportion of birds subject to pre-shipment testing will be raised from 10% to 30%.

    The risk of further spread of HPAI in South Korea is not considered by the ministry to be high. This is based on experience from 2024, when just four outbreaks were reported in the country during the months of July and August. 

    These latest outbreaks bring South Korea’s total since October of 2024 to 49.

    HPAI developments elsewhere in Asia-Pacific birds

    Animal health agencies of Australia and Japan have recently declared to WOAH that earlier HPAI outbreak series in their respective countries have been “resolved.”

    In Australia, a total of more than 596,000 poultry were directly impacted by the disease at four farms in the state of Victoria earlier this year. All these outbreaks started during the month of February, with birds testing positive for the H7N8 serotype of HPAI.

    The H5N1 HPAI virus was detected at a total of 51 poultry farms in Japan between October of 2024 and January of this year. As a result, more than 9.2 million birds died or were culled and destroyed to prevent the further spread of the virus.

    Among Japan’s wild birds, however, the HPAI situation is ongoing.

    After a hiatus of more than two years, the H5N2 variant of HPAI was detected in a wild bird in April, according to a retrospective report to WOAH.

    More than 100 wild birds have also tested positive for the H5N1 virus serotype in Japan over recent months, according to a separate notification.

    Furthermore, the same virus variant was detected after three sea otters were found dead around the island of Hokkaido in early May.  

    Most recent disease update from the Department of Agriculture’s Bureau of Animal Industry (dated June 26) in the Philippines indicates no new HPAI cases in poultry since the end of April.

    As of June 16, nine HPAI outbreaks had occurred in Vietnamese poultry so far this year, reported DanViet, citing agriculture ministry data. Across six provinces, more than 21,300 birds had died, and 25,200 had been culled in 2025 up to that point.

    Compared with 2024, the number of provinces affected this year is lower, but more than twice as many poultry have been lost to the disease, according to this source.   

    Further human infections reported in Cambodia, China

    Cambodia has been experiencing a recent spike in human infections with the avian influenza A(H5N1) virus.

    A recent update by Avian Flu Diary puts the country’s total cases so far this year at seven. Of these, four have been confirmed during the month of June. This was the situation on June 24, based on data from the country’s health ministry.

    As in previous cases in Cambodia, the latest patient is known to have had contact with sick and dead poultry. 

    The source notes that several of those people infected there have died. This is linked to the greater virulence of the virus circulating in the country — recently designated as clade 2.3.2.1e — than the clade 2.3.4.4b variant circulating elsewhere, including in the U.S. and Europe.

    In recent weeks, four human infections with flu viruses of avian origin have been confirmed in China. These are covered in recent updates on the situation in the Western Pacific Region from the World Health Organization (WHO).

    Three of these involved the H9N2 virus — one in each of the provinces of Henan, Hunan, and Sichuan. All started in mid-May following contact with poultry. Two adult patients required hospital treatment, but they and a six-year-old boy are reported to have recovered.

    The fourth Chinese patient was a farmer from Shaanxi province who may have contracted an H10N3 infection while traveling in Inner Mongolia. While still under treatment in hospital, her condition was reported to be improving. This is the sixth confirmed human infection with this virus in the world.

    View our continuing coverage of the global avian influenza situation in poultry, and on disease developments in the U.S. dairy sector.

    Continue Reading